The Company began trading under a new symbol on the Nasdaq, “HYFT”, effective September 4, 2025. The executive headquarters of the Company are situated at Industrious 823 Congress Ave, Suite 300, Austin, Texas 78701. The registered and records office of the Company is located at 1600 – 925 West Georgia Street, Vancouver, British Columbia V6C 3L2, Canada.
Discovery · ActiveModality: AI-designed antibody lead candidate
Partnerships Biotheus (Material Transfer and Evaluation Agreement)
Indications
hypoxic solid tumors(Discovery)
Status note Lead candidate being evaluated by Biotheus for development of novel bispecific antibodies; company out-licenses assets prior to clinical trials.
MDWK-03
Stage not disclosed · Active
Target SARS-CoV-2
Indications
SARS-CoV-2 infection(Stage not disclosed)
Status note Described as the most clinically advanced asset in the broader Vault by stage, in final drug product form; phase not stated.
Per-asset detail extracted from the 20-F filed 2026-07-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.